Latest Breaking News On - Investors relations department sustainability - Page 1 : comparemela.com

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesComunidad autonoma de catalunaGrifols procleix arboplexAntonio martGrifol procleix arboplexGrifols procleixInvestors relations department sustainabilitySpanish stock exchangeMedia press officeGrifol procleix arboplex assayProcleix arboplex assayVitro diagnostic regulationWest nileProcleix arboplexGrifols procleix arboplex assayGrifols diagnostic business

Grifols, S A : Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols, S A : Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaUnited statesGrifols procleixAntonio martGrifol procleix arboplexDennis riedlGrifols procleix arboplexSpanish stock exchangeMedia press officeInvestors relations department sustainabilityGrifol procleix arboplex assayProcleix arboplex assayVitro diagnostic regulationWest nileProcleix arboplexGrifols procleix arboplex assay

Grifols announces positive topline phase 3 fibrinogen clinical trial results

In the AdFIrst study, Biotest s fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired.

Comunidad autonoma de catalunaUnited statesIg yimmugoVictor grifols deuBiotest adfirstMedia press officeGrifols groupInvestors relations department sustainabilitySpanish stock exchangeGrifols chief scientific innovationGrifols chief operatingAdjusted fibrinogen replacement strategyNorth americaMiddle eastMercado continuoRoyal legislative decree

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer s Vaccine at CTAD

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer s Vaccine at CTAD
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBaja californiaComunidad autonoma de catalunaBoada roviraJose terencioTeaes tesaesAlzheimer associationSpanish stock exchangeMedia press officeInvestors relations department sustainabilityAce alzheimer centerGrifols groupBiotech presents positive final resultsMini mental state examinationDisease factsRepeatable battery

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer s Vaccine at CTAD

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer s Vaccine at CTAD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBaja californiaComunidad autonoma de catalunaTeaes tesaesBoada roviraJose terencioGrifols groupInvestors relations department sustainabilityAlzheimer associationMedia press office telSpanish stock exchangeAce alzheimer centerMini mental state examinationDisease factsRepeatable batteryNeuropsychological status